<DOC>
	<DOCNO>NCT00351858</DOCNO>
	<brief_summary>The purpose study determine safety efficacy investigational trifunctional anti-Her-2/neu x anti-CD3 antibody ertumaxomab treatment hormone therapy refractory Her-2/neu 1+ 2+ express advanced metastatic breast cancer</brief_summary>
	<brief_title>Safety Efficacy Study Trifunctional Antibody Ertumaxomab Treat Patients With Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>A multi-centre , phase II study ertumaxomab metastatic breast cancer patient become progressive hormonal therapy . Each eligible patient receive three ascend dos ertumaxomab , administer intravenously . Ertumaxomab administer 3-hour constant rate infusion dose interval 7 day . Each patient participate study 7 month ( include 21 day screen period , 14 day treatment period , 180 days/6 month follow-up ) , 3-monthly post-study follow-up patient become progressive .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Female gender , childbearing potential must negative pregnancy test result within 2 day enrolment must agree practice effective birth control study . Aged 18 year old . Histologically cytologically confirm invasive breast cancer stage IIIb IV disease document progression . Measurable disease accord RECIST . Histologically document advanced primary breast cancer biopsy metastatic site demonstrate HER2/neu expression ( HER2/neu 1+ 2+ , determine immunohistochemistry [ IHC ] ) . HER2/neu 2+ patient must negative Fluorescence In Situ Hybridization [ FISH ] test result . Hormone receptor status Estrogen Receptors ( ERs ) positive and/or Progesterone Receptors ( PRs ) positive . No prior treatment mouse rat antibody . Life expectancy least six month ( life expectancy patient unspecified allow enter study ) . An Eastern Cooperative Oncology Group ( ECOG ) performance score £ 1 . Patients must disease progression hormonal therapy include least one aromatase inhibitor . Adequate hematological , liver kidney function : Thrombocytes ³ 100000 / mm³ ( = 100 x 109 /l ) Hemoglobin ³ 10 g/dl Neutrophil count ³ 1500/mm³ ( = 1.5 x 109 /l ) WBC ³ 3 X 109 /l Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvate transaminase ( SGPT ) ≤ 2.5 x upper limit normal ( ULN ) Serum bilirubin ≤ 2 x ULN Creatinine ≤ 1.5 x ULN clearance ³ 60 ml/min No lifethreatening visceral disease . No known brain central nervous system metastasis . No symptomatic pleural effusion . No symptomatic pericardial effusion . No subject whose site metastatic involvement bone metastases exception measurable soft tissue component bone lesion see image require palliative radiation intervention and/or patient lytic bone lesion ³ 1 cm measure radiography follow evidence recalcification . No history relevant cardiovascular disease : LVEF within institutional range normal measure echocardiogram MUGA scan No prior uncontrolled symptomatic congestive heart failure NYHA ³ 2 No myocardial infarction within past two year No uncontrolled symptomatic cardiac arrhythmia No severe dyspnea . No pulmonary dysfunction need continuous supportive oxygen inhalation . No concurrent uncontrolled comorbid illness . No concurrent malignancy , except treat basal cell squamous cell carcinoma skin , situ carcinoma cervix . Patients document autoimmune disease ( lupus ) exclude participation study unless waiver grant responsible medical monitor . Patients human immunodeficiency virus , hepatitis B hepatitis C positive status exclude participation study . No prior concurrent chemotherapy regimen advance metastatic disease . Prior neoadjuvant adjuvant chemotherapy allow provide stop least six month study entry . No concurrent hormone therapy ( hormone therapy must stop screen visit ) . At least 4 week since prior radiotherapy . No concurrent immune therapy . No concurrent corticosteroid therapy . No regularly use medication health condition comorbidity might result undue risk patient . No prior investigational treatment advance metastatic disease . Able willing comply fully protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>investigational drug</keyword>
	<keyword>drug therapy</keyword>
	<keyword>Antineoplastic Protocols</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Advanced breast cancer</keyword>
	<keyword>Stage III IV breast cancer</keyword>
	<keyword>Hormonal therapy refractory</keyword>
	<keyword>Failure hormonal therapy</keyword>
	<keyword>Her-2/neu express breast cancer</keyword>
	<keyword>low moderate Her-2/neu expression</keyword>
</DOC>